Inactive Instrument

Neuralstem, Inc. Stock NYSE

US64127R3021

End-of-day quote NYSE
- ^USD	-

08-11	Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target	MT

Latest news : Neuralstem, Inc.

08-11	Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target	MT
06-30	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Small Cap Comp Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2500 Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Index	CI
06-29	Palisade Bio Receives FDA Clearance Of IND For PALI-2108 And Plans To Initiate Global Phase 2 ASCENTRA-UC Study In Ulcerative Colitis	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Value Benchmark	CI
06-29	Palisade Bio Shares Rise After FDA Clears PALI-2108 for Phase 2 Trial	DJ
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Microcap Value Benchmark Index	CI
06-29	Palisade Bio Gets FDA IND Clearance for Phase 2 PALI-2108 UC Study	MT
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Microcap Growth Benchmark Index	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 3000E Growth Benchmark	CI

More news

Analysts' recommendations: Neuralstem, Inc.

07-23	Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target	MT
03-26	HC Wainwright Initiates Coverage on Palisade Bio With Buy Rating, $7 Price Target	MT
02-25	Stifel Initiates Palisade Bio at Buy With $5 Price Target	MT
01-09	B. Riley Initiates Palisade Bio at Buy With $7 Price Target	MT
17/11/23	Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	MT

More recommendations

Press Releases: Neuralstem, Inc.

08-11	Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development	AQ
07-10	Palisade Bio to Participate in the Leerink Partners Therapeutics Forum	AQ
06-29	Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis	AQ
06-11	Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors	AQ
06-10	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium	AQ

More press releases

News in other languages: Neuralstem, Inc.

30/01/24	MÄRKTE USA/Fester - Neue Rekordhochs dank sinkender Anleihezinsen
29/01/24	LATE BRIEFING - Unternehmen und Märkte
29/01/24	MÄRKTE USA/Kaum verändert - Vor Fed-Entscheid dominiert Zurückhaltung
29/01/24	MÄRKTE USA/Wall Street startet wenig verändert in Fed-Woche
29/01/24	MÄRKTE USA/Wall Street wenig verändert erwartet

More news

Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.

Employees

Sector

More about the company

Market Cap	373M 322M 302M 275M 517M 35.66B 524M 3.54B 1.39B 17.86B 1.4B 1.37B 59.43B	P/E 2026 *	-9.51x	P/E 2027 *	-7.75x
Enterprise Value	275M 238M 223M 203M 382M 26.32B 387M 2.61B 1.02B 13.18B 1.03B 1.01B 43.86B	EV / Sales 2026 *	771x	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

	2026 *	2027 *
Net sales	357K 308K 289K 263K 495K 34.15M 502K 3.39M 1.33M 17.11M 1.34M 1.31M 56.91M	-
Net income	-47.86M -41.32M -38.76M -35.31M -66.39M -4.58B -67.31M -454M -178M -2.29B -180M -176M -7.63B	-63.05M -54.43M -51.06M -46.51M -87.45M -6.03B -88.66M -599M -235M -3.02B -237M -232M -10.05B
Net Debt	-97.7M -84.34M -79.13M -72.07M -136M -9.34B -137M -928M -363M -4.68B -367M -359M -15.57B	-335M -289M -271M -247M -464M -32B -471M -3.18B -1.25B -16.03B -1.26B -1.23B -53.33B

Neuralstem, Inc. Stock NYSE

Stocks

US64127R3021

Valuation: Neuralstem, Inc.

Latest news : Neuralstem, Inc.

Analysts' recommendations: Neuralstem, Inc.

Press Releases: Neuralstem, Inc.

News in other languages: Neuralstem, Inc.

Financials

Company Profile